Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Continue your routine care with us by scheduling an in-person appointment or Video Visit.

Bosutinib (Bosulif®)

Bosutinib is a tyrosine kinase inhibitor (TKI) that targets the BCR-ABL protein. It is approved by the FDA only in patients that have first been treated with another TKI. In that setting, it can be used to treat Chronic, Accelerated, and Blast Phase CML.

Side Effects

These side effects are common when patients start therapy but are usually mild to moderate. Most of these side effects improve over time but it is important to tell your doctor about any side effects you may be experiencing. Supportive medications can help with symptoms from these side effects and often, the TKI doses do not need to be modified.

  • Diarrhea
  • Muscle pain/aches
  • Edema (fluid buildup) around the eyes, feet, or abdomen
  • Pruritus (itchy skin) and skin rashes
  • Fatigue
  • Nausea
  • Decreased white blood cell and platelet counts

Additional Information: https://medlineplus.gov/druginfo/meds/a613005.html

Richard T. Silver MD Myeloproliferative Neoplasms Center 525 East 70th St., Starr Pavillion, 3rd Floor New York, NY 10021 SilverMPNCenter@med.cornell.edu